Abstract
The molecular chaperone heat shock protein 90 (Hsp90) is required for stability and function of multiple mutated, chimeric, and over-expressed signaling proteins that promote cancer cell growth and / or survival. It is also critical for the function of many normally expressed proteins, including protein kinases, steroid receptors and other transcription factors, and it may protect the cell from incapacitating or deleterious mutations. The recent identification of a nucleotide binding pocket within the first 220 amino acids of the protein, together with the discovery that at least two structurally distinct classes of antibiotic can replace nucleotide at this site and alter chaperone activity, has deservedly focused attention on Hsp90s amino terminus as an important regulator of function. However, data continue to accumulate pointing to the Cterminal half of the chaperone as an equally important regulator of activity, and small molecules that bind to this portion of Hsp90 have been identified.
Keywords: C-Terminal, chimeric, nucleotide
Current Cancer Drug Targets
Title: The C-Terminal Half of Heat Shock Protein 90 Represents a Second Site for Pharmacologic Intervention in Chaperone Function
Volume: 3 Issue: 5
Author(s): Monica G. Marcu and Leonard M. Neckers
Affiliation:
Keywords: C-Terminal, chimeric, nucleotide
Abstract: The molecular chaperone heat shock protein 90 (Hsp90) is required for stability and function of multiple mutated, chimeric, and over-expressed signaling proteins that promote cancer cell growth and / or survival. It is also critical for the function of many normally expressed proteins, including protein kinases, steroid receptors and other transcription factors, and it may protect the cell from incapacitating or deleterious mutations. The recent identification of a nucleotide binding pocket within the first 220 amino acids of the protein, together with the discovery that at least two structurally distinct classes of antibiotic can replace nucleotide at this site and alter chaperone activity, has deservedly focused attention on Hsp90s amino terminus as an important regulator of function. However, data continue to accumulate pointing to the Cterminal half of the chaperone as an equally important regulator of activity, and small molecules that bind to this portion of Hsp90 have been identified.
Export Options
About this article
Cite this article as:
Marcu G. Monica and Neckers M. Leonard, The C-Terminal Half of Heat Shock Protein 90 Represents a Second Site for Pharmacologic Intervention in Chaperone Function, Current Cancer Drug Targets 2003; 3 (5) . https://dx.doi.org/10.2174/1568009033481804
DOI https://dx.doi.org/10.2174/1568009033481804 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Interactions of Anti-Cancer Drugs Approved in the Last Decade in the United States with Membrane Transporters
Anti-Cancer Agents in Medicinal Chemistry Extracellular Hsp70: Export and Function
Current Protein & Peptide Science CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Metabolomic Approach in Probing Drug Candidates
Current Topics in Medicinal Chemistry Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Inflammatory Responses in Brain Ischemia
Current Medicinal Chemistry Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Extracellular Vesicles as Therapeutics for Brain Injury and Disease
Current Pharmaceutical Design Targeting Nitrosative Stress for Neurovascular Protection: New Implications in Brain Diseases
Current Drug Targets The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Current Pharmaceutical Design Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry A Role of Immunotherapy in Metastatic Malignant Melanoma
Central Nervous System Agents in Medicinal Chemistry Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists
Current Medicinal Chemistry Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Erythropoietin Gene Polymorphism rs551238 is Associated with a Reduced Susceptibility to Brain Injury in Preterm Infants
Current Neurovascular Research Effects of Nucleosides on Glia - Neuron Interactions Open up New Vistas in the Development of More Effective Antiepileptic Drugs
Current Medicinal Chemistry Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry The Antimicrobial Activity of Red Sour Cherry (Prunus cerasus L.) Extracts: II. Measurement of Sensitivity and Attenuation of Gram-Positive and Gram-Negative Bacteria and C. albicans in Culture
Current Nutrition & Food Science Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry